Effects of enhanced pacing modalities on health care resource utilization and costs in bradycardia patients: An analysis of the randomized MINERVA trial

摘要: Background Many patients who suffer from bradycardia and need cardiac pacing also have atrial fibrillation (AF). New pacemaker algorithms, such as preventive antitachycardia (DDDRP) managed ventricular (MVP), been specifically designed to reduce AF occurrence duration minimize the detrimental effects of right pacing. The randomized MINimizE Right Ventricular prevent Atrial heart failure trial established that DDDRP + MVP modality reduced permanent in compared with standard dual-chamber (DDDR). Objective aim this study was estimate cost savings due lower AF-related health care utilization events based on costs United States European Union. Methods Dual-chamber a history paroxysmal or persistent were randomly assigned receive DDDR (n = 385) advanced features (DDDRP MVP; n=383). We used published Union (Italy, Spain, Kingdom) associated hospitalizations emergency visits. Results rate significantly group than conventional (DDDR group; 42% reduction; incidence ratio 0.58). Similarly, significant reduction 68% observed for department visits (incidence 0.32; P Conclusion algorithms successfully utilization, resulting payers.